Form 13-F position report

FORTE BIOSCIENCES

Reported by The Goldman Sachs Group Inc

FBRX CUSIP 34962G109 Manager CIK 0000886982

Reported 20,776 shares, up 2 (0.0%) from the prior quarter.

Reported value -22.9%; share count 0.0% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 20,776 Quarter-end amount reported
Reported value $11,157 Fair value at quarter end
Consecutive quarters held 14 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 39000
2021-12-31 182000
2022-03-31 40000
2022-06-30 43000
2022-09-30 22000
2022-12-31 20333
2023-03-31 20828
2023-06-30 21652
2023-09-30 22346
2023-12-31 17042
2024-03-31 14463
2024-06-30 11157
2024-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for FORTE BIOSCIENCES held by The Goldman Sachs Group Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2024 Reduced 0 -20,776 (-100.0%) 0 $0 2024-11-14
Q2 2024 Added 20,776 +2 (0.0%) < 0.01% $11,157 2024-08-13
Q1 2024 Added 20,774 +34 (0.2%) < 0.01% $14,463 2024-05-15
Q4 2023 Reduced 20,740 -13,016 (-38.6%) < 0.01% $17,042 2024-02-13
Q3 2023 Added 33,756 +12,937 (62.1%) < 0.01% $22,346 2023-11-14
Q2 2023 Added 20,819 +197 (1.0%) < 0.01% $21,652 2023-08-15
Q1 2023 Added 20,622 +289 (1.4%) < 0.01% $20,828 2023-05-11
Q4 2022 Reduced 20,333 -50 (-0.2%) < 0.01% $20,333 2023-02-13
Q3 2022 Reduced 20,383 -12,419 (-37.9%) < 0.01% $22,000 2022-11-14
Q2 2022 Added 32,802 +5,182 (18.8%) < 0.01% $43,000 2022-08-15
Q1 2022 Reduced 27,620 -57,620 (-67.6%) < 0.01% $40,000 2022-05-16
Q4 2021 Added 85,240 +72,206 (554.0%) < 0.01% $182,000 2022-02-14
Q3 2021 Reduced 13,034 -24,869 (-65.6%) < 0.01% $39,000 2021-11-10
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

38 managers reported FORTE BIOSCIENCES for Q2 2024.

Managers reporting FORTE BIOSCIENCES in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
TYBOURNE CAPITAL MANAGEMENT HK LTD Unchanged 3,624,548 0 0.4% $1,946,383 4 qtrs
PERCEPTIVE ADVISORS LLC Unchanged 3,265,359 0 0.04% $1,753,498 4 qtrs
BVF INC IL Unchanged 2,982,105 0 0.04% $1,601,390 4 qtrs
Cable Car Capital LP Unchanged 2,031,987 0 1.15% $1,091,177 3 qtrs
FRED ALGER MANAGEMENT LLC Unchanged 1,838,965 0 < 0.01% $987,524 4 qtrs
FARALLON CAPITAL MANAGEMENT LLC Unchanged 1,810,455 0 < 0.01% $972,214 4 qtrs
BML Capital Management LLC Unchanged 1,761,702 0 0.68% $946,034 7 qtrs
VANGUARD GROUP INC Unchanged 665,230 0 < 0.01% $357,228 17 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 346,292 +2,860 < 0.01% $186,008 17 qtrs
BlackRock Inc Unchanged 174,858 0 < 0.01% $93,899 17 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 13, 2024
Filing type
13F-HR
Position type
CMN

Voting authority reported

Sole
20,776
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.